Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Moderna, Inc. (MRNA) Price & Performance

AMC trades at $2.465, up 1.86% on the day, with a bullish technical signal and recent earnings beats. The company reported record revenue and EBITDA in Q2 2026, with improving cash flow trends. However, it remains unprofitable with a net income margin of -10.59% and negative shareholder equity of -$1.76 billion. Analyst consensus is mixed with a $3.00 price target.

Outlook hinges on sustained box office recovery and cost discipline to achieve profitability. Key risks include high debt load, competitive pressures, and reliance on blockbuster films. Upside potential exists if operational improvements continue, but financial stability remains a concern for investors.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.